http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2700105-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d584042a524740a406723fe1631e49e5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B6-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K103-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B6-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2019-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa86a99f672c7fcefc51d2111f48e012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf3cb7eed1af88fa14dc24f6c912a644 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a73e6516c59252970d4dbc2bc721b93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c8dadd73680a5492e0887dd1058148b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e297bb69e0b9450d0edf0c94bdda3d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e6f7855cc6bd9e5c308d7e5983a4802 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02b733591306b04382eb874bc0dfc6ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4798285530dbe0e17c57ea1c7f32b791 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_476e344e3b046ed0bb45bc8be9e1682d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eecc407bc478d90f3e34e10aa3849f24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79d0986f88c4cc1401ca4ab4cfa6b7fe |
| publicationDate | 2019-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2700105-C1 |
| titleOfInvention | Method for assessing the effectiveness of chemotherapy for malignant lymphomas |
| abstract | FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology and radiation diagnostics, and can be used for assessing the effectiveness of chemotherapy for malignant lymphomas. One-photon emission computed tomography (OPECT) is performed twice: before and two weeks after completion of chemotherapy in patients with initially high accumulation of radiopharmaceutical (RP) in the tumor. That is ensured by administering a radiopharmaceutical preparation based on technetium-99m-labeled glucose derivative prepared immediately before administration. For this purpose 4 ml of sodium pertechnetate NaTcOfrom a generator under aseptic conditions is introduced by means of a syringe into a bottle with a reagent consisting of: 1-thio-D-glucose sodium salt of hydrate 0.625 mg, tin dichloride 2-water 0.044–0.052 mg, ascorbic acid not more than 0.125 mg, sodium chloride 8.0–10.0 mg, water for injection up to 1 ml. Content of the vial is mixed by shaking, incubated at room temperature for 30 minutes until complete dissolution of the reagent. Intravenous is administered RP in dose of 500 MBq. In 40 minutes after administration RP one-photon emission computed tomography is carried out on a two-detector gamma camera. Obtained images are subjected to postprocessing. In the absence of hyperfixation foci RP repeated reassessment involves complete remission of malignant lymphoma. Presence of hyperfixation areas RP in tissue of lymph nodes and extranodally indicates resistance of malignant lymphoma to chemotherapy.EFFECT: high information value and accessibility of the method.1 cl, 2 dwg, 2 ex |
| priorityDate | 2019-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.